Letter to the Editor: Evaluation of IL-33 and IL-34 Plasma Levels in a Cohort of Multiple Myeloma Patients in Northeast Brazil

Baghdadi M , Ishikawa K , Nakanishi S , Murata T , Umeyama Y , Kobayashi T , Kameda Y , Endo H , Wada H , Bogen B , Yamamoto S , Yamaguchi K , Kasahara I , Iwasaki H , Takahata M , Ibata M , Takahashi S , Goto H , Teshima T , Seino KI . 2019. A role for IL-34 in osteolytic disease of multiple myeloma. Blood Adv, 3(4):541–551.

Baghdadi M , Endo H , Tanaka Y , Wada H , Seino KI . 2017. Interleukin 34, from pathogenesis to clinical applications. Cytokine, 99:139–147.

Chen Z , Buki K , Vääräniemi J , Gu G , Väänänen K . 2013. The critical role of IL-34 in osteoclastogenesis, PLoS One 6(4):e18689.

Musolino C , Allegra A , Profita M , Alonci A , Saitta S , Russo S , Bonanno A , Innao V , Gangemi S . 2013. Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease. Br J Haematol, 160(5):709–710.

Wang J , Faict S , Maes K , De Bruyne E , Van Valckenborgh E , Schots R , Vanderkerken K , Menu E . 2016. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma. Oncotarget, 7(25):38927–38945.